Speeding up the diagnosis of multidrug-resistant tuberculosis in a high-burden region with the use of a commercial line probe assay

Brandao, Angela Pires; Pinhata, Juliana Maira Watanabe; Oliveira, Rosangela Siqueira; Galesi, Vera Maria Neder; Caiaffa-Filho, Helio Hehl; Ferrazoli, Lucilaine.
J. bras. pneumol ; 45(2): e20180128, 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1002440

Documentos relacionados

  1. A host blood transcriptional signature differentiates multi-drug/rifampin-resistant tuberculosis (MDR/RR-TB) from drug susceptible tuberculosis: a pilot study.
  2. Evaluation of a Molecular Test for Detection of Mycobacterium tuberculosis Isolates Resistant to Rifampicin and Isoniazid.
  3. Detection of Isoniazid and Rifampin Resistance in Mycobacterium tuberculosis Clinical Isolates from Sputum Samples by High-Resolution Melting Analysis.
  4. Direct Detection of Fluoroquinolone Resistance in Sputum Samples from Tuberculosis Patients by High Resolution Melt Curve Analysis.
  5. Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid.
  6. Rifampicin drug resistance and host immunity in tuberculosis: more than meets the eye.
  7. Loss-of-function mutations in <i>ndh</i> do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in <i>Mycobacterium tuberculosis</i>.
  8. Regional distribution of Mycobacterium tuberculosis infection and resistance to rifampicin and isoniazid as determined by high-resolution melt analysis.
  9. MDR Tuberculosis Treatment.
  10. TB or not TB? Definitive determination of species within the Mycobacterium tuberculosis complex in unprocessed sputum from adults with presumed multidrug-resistant tuberculosis.